Cargando…

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study

OBJECTIVE: To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS: Baseline pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360279/
https://www.ncbi.nlm.nih.gov/pubmed/28148544
http://dx.doi.org/10.2337/dc16-1875
_version_ 1782516563258114048
author Saremi, Aramesh
Howell, Scott
Schwenke, Dawn C.
Bahn, Gideon
Beisswenger, Paul J.
Reaven, Peter D.
author_facet Saremi, Aramesh
Howell, Scott
Schwenke, Dawn C.
Bahn, Gideon
Beisswenger, Paul J.
Reaven, Peter D.
author_sort Saremi, Aramesh
collection PubMed
description OBJECTIVE: To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS: Baseline plasma levels of methylglyoxal hydroimidazolone, Nε-carboxymethyl lysine, Nε-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS: In risk factor–adjusted multivariable regression models, G-H1 was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS: Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the “negative metabolic memory” of macrovascular complications in people with long-standing T2D.
format Online
Article
Text
id pubmed-5360279
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-53602792018-04-01 Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study Saremi, Aramesh Howell, Scott Schwenke, Dawn C. Bahn, Gideon Beisswenger, Paul J. Reaven, Peter D. Diabetes Care Cardiovascular and Metabolic Risk OBJECTIVE: To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS: Baseline plasma levels of methylglyoxal hydroimidazolone, Nε-carboxymethyl lysine, Nε-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS: In risk factor–adjusted multivariable regression models, G-H1 was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS: Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the “negative metabolic memory” of macrovascular complications in people with long-standing T2D. American Diabetes Association 2017-04 2017-02-01 /pmc/articles/PMC5360279/ /pubmed/28148544 http://dx.doi.org/10.2337/dc16-1875 Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
spellingShingle Cardiovascular and Metabolic Risk
Saremi, Aramesh
Howell, Scott
Schwenke, Dawn C.
Bahn, Gideon
Beisswenger, Paul J.
Reaven, Peter D.
Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
title Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
title_full Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
title_fullStr Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
title_full_unstemmed Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
title_short Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
title_sort advanced glycation end products, oxidation products, and the extent of atherosclerosis during the va diabetes trial and follow-up study
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360279/
https://www.ncbi.nlm.nih.gov/pubmed/28148544
http://dx.doi.org/10.2337/dc16-1875
work_keys_str_mv AT saremiaramesh advancedglycationendproductsoxidationproductsandtheextentofatherosclerosisduringthevadiabetestrialandfollowupstudy
AT howellscott advancedglycationendproductsoxidationproductsandtheextentofatherosclerosisduringthevadiabetestrialandfollowupstudy
AT schwenkedawnc advancedglycationendproductsoxidationproductsandtheextentofatherosclerosisduringthevadiabetestrialandfollowupstudy
AT bahngideon advancedglycationendproductsoxidationproductsandtheextentofatherosclerosisduringthevadiabetestrialandfollowupstudy
AT beisswengerpaulj advancedglycationendproductsoxidationproductsandtheextentofatherosclerosisduringthevadiabetestrialandfollowupstudy
AT reavenpeterd advancedglycationendproductsoxidationproductsandtheextentofatherosclerosisduringthevadiabetestrialandfollowupstudy